FDA extends review of argenx's subcutaneous efgartigimod, pushing decision date back into June
Fierce Pharma
JANUARY 31, 2023
FDA extends review of argenx's subcutaneous efgartigimod, pushing decision date back into June ntaylor Tue, 01/31/2023 - 06:29
221 
Let's personalize your content